D. Dvorakova

发表

A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice.

Z. Bortlíček, Š. Pospíšilová, M. Navrátil, 2012, Experimental hematology.

The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for ‘a lymphoma stem cell’

J. Šmardová, L. Křen, D. Dvořáková, 2009, Leukemia & lymphoma.

Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment

Š. Pospíšilová, J. Šmardová, D. Dvořáková, 2006, Leukemia.

Interleukin-2 activation of haematopoietic stem cells.

L. Dušek, R. Hájek, M. Penka, 2002, Acta medica Austriaca.

A Complex Role for FGF-2 in Self-Renewal, Survival, and Adhesion of Human Embryonic Stem Cells

Š. Pospíšilová, V. Kríz, A. Hampl, 2009, Stem cells.

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population†

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, American journal of hematology.

Perioperative interstitial CT-based brachytherapy boost in breast cancer patients with breast conservation after neoadjuvant chemotherapy.

K. Stastný, D. Dvořáková, J. Vaňásek, 2012, Neoplasma.

Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families

L. Kozák, L. Fajkusová, V. Romano, 1995, Human Genetics.

Fibroblast growth factor signaling in embryonic and cancer stem cells

Ales Hampl, A. Hampl, P. Dvořák, 2006, FEBS letters.

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

A. Stukalov, M. Cazzola, J. Colinge, 2012, American journal of hematology.

Expression and Potential Role of Fibroblast Growth Factor 2 and Its Receptors in Human Embryonic Stem Cells

A. Hampl, P. Dvořák, D. Dvořáková, 2005, Stem cells.

Clonal hierarchy of main molecular lesions in acute myeloid leukaemia

J. Mayer, Z. Ráčil, A. Folta, 2019, British journal of haematology.

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.

Martin Klabusay, Michael Doubek, D. Dvořáková, 2009, Experimental hematology.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry

P. Šimara, S. Stejskal, I. Koutná, 2014 .

Prospective analysis of low-level BCR–ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia

D. Dvořáková, J. Mayer, Z. Ráčil, 2014, Leukemia & lymphoma.

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels

L. Dušek, H. Klamová, M. Karas, 2013, Cancer medicine.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials

L. Dušek, H. Klamová, J. Mužík, 2013, Leukemia & lymphoma.

The BCR–ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

Š. Pospíšilová, J. Šmardová, D. Dvořáková, 2013, Leukemia & lymphoma.

BCR–ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response

P. Šimara, S. Stejskal, I. Koutná, 2012, Leukemia & lymphoma.

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

H. Klamová, J. Mayer, Z. Ráčil, 2011, International journal of hematology.

Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

L. Dušek, H. Klamová, J. Březinová, 2011, American journal of hematology.

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects

P. Valent, H. Herrmann, I. Sadovnik, 2016, Oncotarget.

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR–ABL transcript causing false-negative results by standard polymerase chain reaction

J. Mayer, F. Rázga, D. Zackova, 2010, Leukemia & lymphoma.

Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular diagnosis & therapy.

Infusion of HLA-mismatched peripheral blood stem cells duringtreatment AML in elderly patients

D. Dvořáková, J. Mayer, Z. Ráčil, 2014 .

Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia

D. Dvořáková, J. Vorlíc̆ek, M. Doubek, 2006, Bone Marrow Transplantation.

Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia

A. Hampl, P. Dvořák, D. Dvořáková, 2003, Leukemia.

A Case of a Novel PML/RARA Short Fusion Transcript with Truncated Transcription Variant 2 of the RARA Gene

D. Dvořáková, M. Doubek, J. Mayer, 2010, Molecular Diagnosis & Therapy.

Preliminary view on owner’s and manager’s approach to valuation

B. Knapová, Jiří Strouhal, D. Dvorakova, 2009 .

Visible . A Service of zbw

H. Alfen, Dirk Daube, D. Dvorakova, 2011 .

Fair Value and Application of Fair Value in IAS/IFRS

D. Dvorakova, 2006 .

Should be fair value a single measurement base in financial accounting

D. Dvorakova, 2011 .

Developments in Fair Value Measurement: Some IFRS 13 View

D. Dvorakova, 2011 .

Fair Value Measurement of Assets and Issue of Capital Maintenance

D. Dvorakova, 2012 .

Auditing of SMEs: Issues caused by international harmonization of financial reporting (from Czech perspective)

Adela Deaconu, L. Müllerová, Marie Paseková, 2011 .

New opportunities from farm accounting

Dana Dvořáková, D. Dvorakova, 2006 .

TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.

Š. Pospíšilová, D. Dvořáková, J. Skřičková, 2014, Lung cancer.

Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia

G. Juliusson, L. Pettersson, M. Ehinger, 2016, Genes, chromosomes & cancer.

The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice

J. Chovancová, V. Bystrý, D. Dvořáková, 2018, Journal of Cancer Research and Clinical Oncology.

Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.

Š. Pospíšilová, M. Navrátil, D. Dvořáková, 2011, Neoplasma.

Significance of qualitative PCR detection method for preemptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation -- single-centre experience.

J. Mayer, Z. Ráčil, D. Škapová, 2005, Neoplasma.

Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplants of allogeneic peripheral blood stem cells

A. Hampl, J. Fajkus, P. Dvořák, 2001, British journal of haematology.

FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias

A. Hampl, P. Dvořák, D. Dvořáková, 2001, Leukemia.

[Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors].

J. Starý, K. Michalová, P. Žák, 2008, Vnitrni lekarstvi.

Limited efficacy of HLA‐haploidentical peripheral blood stem cell infusion in treatment of elderly patients with acute myelogenous leukaemia

J. Mayer, Z. Ráčil, O. Horký, 2017, Hematological oncology.

Genesis of new allele at locus D2S1360 in leukemia patient

J. Mayer, M. Krejci, I. Jeziskova, 2017, Leukemia & lymphoma.

Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR.

D. Dvořáková, J. Mayer, Z. Ráčil, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML

D. Dvořáková, J. Mayer, Z. Ráčil, 2015, International Journal of Hematology.

Real-Time PCR Diagnostics Failure Caused by Nucleotide Variability within Exon 4 of the Human Cytomegalovirus Major Immediate-Early Gene

D. Dvořáková, J. Vorlíc̆ek, J. Mayer, 2007, Journal of Clinical Microbiology.

Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2

M. Cazzola, C. Bock, M. Steurer, 2013, PloS one.

[Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].

Z. Zemanová, K. Michalová, J. Stejskal, 2010, Vnitrni lekarstvi.

Significance of qualitative PCR detection method for pre-emptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation--single-centre experience.

D. Dvořáková, J. Mayer, Z. Ráčil, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia.

Š. Pospíšilová, J. Šmardová, B. Tichy, 2008, Molecular immunology.

Haplotype distribution at the phenylalanine hydroxylase locus in PKU families from the Moravian area of Czechoslovakia

L. Kozák, D. Dvořáková, J. Kamarýt, 1993, Journal of Inherited Metabolic Disease.

Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia

D. Dvořáková, J. Mayer, Z. Ráčil, 2017, Leukemia & lymphoma.

Accounting and Reporting for Sustainable Development

D. Dvorakova, 2009 .

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, American journal of hematology.

Bone marrow versus peripheral blood: comparison of thechimerism analysis

J. Mayer, Y. Brychtova, O. Horký, 2009 .

Changes in telomerase activity, expression and splicing in response to differentiation of normal and carcinoma colon cells.

A. Kozubík, J. Fajkus, J. Hofmanová, 2003, Anticancer research.

A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations

D. Dvořáková, J. Pospíšilová, J. Mayer, 2009, Leukemia.

CEBPA Gene Mutational Status

D. Dvořáková, J. Mayer, F. Rázga, 2012, Molecular Diagnosis & Therapy.

Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse

J. Kissová, D. Dvořáková, J. Mayer, 2011, International journal of laboratory hematology.

Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.

D. Dvořáková, J. Hausnerova, J. Skřičková, 2015, Lung cancer.

Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients

D. Dvořáková, P. Žák, J. Mayer, 2019, British journal of haematology.

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.

H. Klamová, J. Moravcová, D. Dvořáková, 2010, Experimental hematology.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types

H. Klamová, J. Mayer, Z. Ráčil, 2011, Leukemia & lymphoma.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Martin C. Müller, D. Colomer, J. Gabert, 2010, Blood.

Monitoring of Epstein–Barr virus load in patients after allogeneic hematopoietic stem cell transplantation

D. Dvořáková, J. Mayer, M. Lengerova, 2012, Infection.

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations

J. Mayer, Z. Ráčil, M. Lengerova, 2010, American journal of hematology.

Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2013, Leukemia & lymphoma.

Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene

J. Mayer, Z. Ráčil, F. Rázga, 2013, Leukemia & lymphoma.

Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, American journal of hematology.

IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, Leukemia & lymphoma.

Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.

J. Hausnerova, J. Skřičková, B. Robešová, 2015, Lung cancer.

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].

Š. Pospíšilová, D. Dvořáková, A. Vašíková, 2013, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Activating mutations in the epidermal growth factor receptor gene in non-small cell lung cancer fixed tissue: Analysis and one center experience

J. Hausnerova, J. Skřičková, B. Robešová, 2012 .

Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse

F. Rázga, O. Horký, L. Kablásková, 2011, International journal of laboratory hematology.